ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
June 01, 2024 09:00 ET
|
ClearPoint Neuro, Inc.
Newly Launched ClearPoint Neuro technology - SmartFrame OR and Prism Laser will be on display at ASSFN in Nashville from June 1 - 4
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
June 01, 2024 09:00 ET
|
Werewolf Therapeutics, Inc.
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical...
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
June 01, 2024 08:15 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, June 01, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fastly, Inc. (NYSE: FSLY) securities between February 15, 2024 and May 1,...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2024 08:15 ET
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that...
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
June 01, 2024 08:15 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
June 01, 2024 08:05 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
June 01, 2024 08:00 ET
|
OkayCoin
Los Angeles, CA, USA, June 01, 2024 (GLOBE NEWSWIRE) -- OkayCoin, a pioneering force in the cryptocurrency staking sphere, today announced a series of strategic initiatives aimed at maximizing...
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
June 01, 2024 08:00 ET
|
Kymera Therapeutics, Inc.
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement...
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
June 01, 2024 08:00 ET
|
Purple Biotech Ltd.
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs....
CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
June 01, 2024 08:00 ET
|
CryptoHeap
Miami, Fl, June 01, 2024 (GLOBE NEWSWIRE) -- CryptoHeap, an innovative leader in cryptocurrency staking services, today announced its ambitious goal to become the top crypto staking platform as...
- June 01, 2024 09:00 ET ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
- May 31, 2024 21:13 ET 2024 Canadian Screen Award Winners Announced